EUS-derived criteria for distinguishing benign from malignant metastatic solid hepatic masses

. Author manuscript; available in PMC: 2017 Aug 29.

Published in final edited form as: Gastrointest Endosc. 2015 Feb 7;81(5):1188–96.e1-7. doi: 10.1016/j.gie.2014.10.035

Indication for EUS	Set 1 (n = 100)		Set 2 (n = 100)
Indication for EUS	Cytology (+)^*	Cytology (−)^*	Cytology (+)^*	Cytology (−)^*
Pancreatic adenocarcinoma	36	10	34	10
Esophageal adenocarcinoma	6	5	6	6
Colorectal adenocarcinoma	1	1	2	0
Gastric adenocarcinoma	2	2	1	2
Ampullary adenocarcinoma	0	0	1	1
Cholangiocarcinoma/gallbladder cancer	3	2	4	2
Adenocarcinoma of unknown primary site	2	0	1	0
Pancreatic neuroendocrine tumor	5	4	6	4
Hepatocellular carcinoma	1	0	1	0
Melanoma	1	0	0	0
Lymphoma	0	1	0	1
Other (gynecologic, genitourinary cancers)	0	3	0	2
Benign lesions	0	15	0	16
Total	57	43	56	44

(+) and (−) apply to the EUS-guided FNA cytologic result from the liver mass itself.